Publications for Delong Liu delong_liu@nymc.edu

Cang, S., Xu, X., Ma, Y., Liu, D., & Chiao, J. W. (2016). Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells. Journal of Hematology & Oncology, 9, 3. doi:10.1186/s13045-016-0233-x 

Chen, Y., Cang, S., Han, L., Liu, C., Yang, P., Liu, D.,. . . Chiao, J. W. (2016). Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells. Oncotarget, 7(18), 26567-26579. doi:10.18632/oncotarget.8440

Katchi, T., Kolandaivel, K., Khattar, P., Farooq, T., Islam, H., & Liu, D. (2016). Extramedullary hematopoiesis presented as cytopenia and massive paraspinal masses leading to cord compression in a patient with hereditary persistence of fetal hemoglobin. Biomarker Research, 4(1), 17. doi:10.1186/s40364-016-0071-6

Li, Z., & Liu, D. (2016). Cell therapy must be regulated as medicine. Experimental Hematology & Oncology, 5, 26. doi:10.1186/s40164-016-0055-0

Linder, K., Gandhiraj, D., Hanmantgad, M., Seiter, K., & Liu, D. (2016). Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: HyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental Hematology & Oncology, 5, 20. doi:10.1186/s40164-016-0051-4

Mamorska-Dyga, A., Ronny, F. M., Puccio, C., Islam, H., & Liu, D. (2016). A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient. Stem Cell Investigation, 3, 25. doi:10.21037/sci.2016.06.06

Mamorska-Dyga, A., Wu, J., Khattar, P., Ronny, F. M., Islam, H., Seiter, K., & Liu, D. (2016). Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: A case report. Stem Cell Investigation, 3, 8. doi:10.21037/sci.2016.03.02

Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., & Liu, D. (2015). Novel agents for advanced pancreatic cancer. Oncotarget, 6(37), 39521-39537. doi:10.18632/oncotarget.3999

Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015). ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. Journal of Hematology & Oncology, 8(1), [Article 129]. doi:10.1186/s13045-015-0224-3

Das, A., & Liu, D. (2015). Novel antidotes for target specific oral anticoagulants. Experimental Hematology & Oncology, 4 [Article 25]. doi:10.1186/s40164-015-0020-3

Iragavarapu, C., Mustafa, M., Akinleye, A., Furqan, M., Mittal, V., Cang, S., & Liu, D. (2015). Novel ALK inhibitors in clinical use and development. Journal of Hematology & Oncology, 8(1), [Article 17]. doi:10.1186/s13045-015-0122-8

Liu, D., Sun, W., Hou, J., Yuan, R., & Li, Z. (2015). Pass quantity, focus on quality. Journal of Hematology & Oncology, 8(1), [Article 27]. doi:10.1186/s13045-015-0123-7

Wu, J., Fu, J., Zhang, M., & Liu, D. (2015). AFM13: A first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Journal of Hematology & Oncology, 8(1), [Article 96]. doi:10.1186/s13045-015-0188-3

Wu, J., Fu, J., Zhang, M., & Liu, D. (2015). Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology, 8(1), [Article 104]. doi:10.1186/s13045-015-0195-4

Zheng, X., Liu, D., Fallon, J. T., & Zhong, M.. (2015). Distinct genetic alterations in small cell carcinoma from different anatomic sites. Experimental Hematology & Oncology, 4, [Article 2].  doi:10.1186/2162-3619-4-2

Cang, S., Ma, Y., Chiao, J. W., & Liu, D. (2014). Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells. Experimental Hematology & Oncology, 3(1), 5. This material can be found here.

Parikh, K., Cang, S., Sekhri, A., & Liu, D. (2014). Review: Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents. Journal of Hematology & Oncology, 7, 78. doi:10.1186/s13045-014-0078-0

Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013). Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of Hematology & Oncology, 6 [Article 88]. doi: 10.1186/1756-8722-6-88

Akinleye, A., Chen, Y., Mukhi, N., Song, Y., & Liu, D. (2013). Ibrutinib and novel BTK inhibitors in clinical development. Journal of Hematology & Oncology, 6 [Article 59]. doi:10.1186/1756-8722-6-59

Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013). MEK and the inhibitors: From bench to bedside. Journal of Hematology & Oncology, 6 [Article 27]. doi:10.1186/1756-8722-6-27

Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013). STAT inhibitors for cancer therapy. Journal of Hematology & Oncology, 6 [Article 90]. doi:10.1186/1756-8722-6-90

Huang, T., Karsy, M., Zhuge, J., Zhong, M., & Liu, D. (2013). B-Raf and the inhibitors: From bench to bedside. Journal of Hematology & Oncology, 6 [Article 30]. doi:10.1186/1756-8722-6-30